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Abstract: Multiple multicomponent reactions rapidly assemble 
complex structures. Despite being very productive, the lack of 
selectivity and the reduced number of viable transformations restrict 
their general application in synthesis. Hereby, we describe a 
rationale for a selective version of these processes based in the 
preferential generation of intermediates which are less reactive than 
the initial substrates. In this way, applying the Groebke-Blackburn-
Bienaymé reaction on a range of -polyamino-polyazines, we 
prepared a family compact heterocyclic scaffolds with relevant 
applications in medicinal and biological chemistry (live cell imaging 
probes, selective binders for DNA quadruplexes and antiviral agents 
against human adenoviruses). The approach has general character 
and yields complex molecular targets in a selective, tunable and 
direct manner. 
Introduction 
Multicomponent reactions (MCRs), processes in which three or 
more reactants interact to yield an adduct, are fundamental in 
the development of synthetic methods, because of their 
remarkable atom and step economies, molecular variability and 
structural diversity.1-3 Isocyanides are pivotal in MCRs, leading 
to the most fruitful processes, the Ugi and Passerini reactions 
being paradigmatic examples.4,5  
Especially attractive in this context is Wessjohann’s 
development of multiple MCRs, which further increases the 
performance of the original formulation. In such impressive 
transformations, bi(poly)functional components undergo a 
productive set of MCRs to assemble large adducts in a single 
step. Through this approach, a variety of extremely complex 
structures, including glycoconjugates, macrocyclic cages, 
peptoid-peptides, etc., was prepared.6-9 This remarkable 
achievement could be upgraded if different reactions were 
selectively performed at the repeated functionalities. However, 
at the present state, all reactive functional groups (mainly linked 
through long alkyl chains) undergo the same transformation in 
an indiscriminate manner. It is worth to mention the remarkable 
exception of Orru’s chemically distinct di-isocyanides, which was 
elaborated up to an 8CR.10 Sequential versions of multiple 
MCRs have been conducted by either blocking an existing 
functional group or by gradually generating new functionalities 
along the process.11,12  
The design of selective multiple MCRs (Scheme 1A) 
constitutes a step forward in the programmed synthesis of 
complex compounds. In principle, such processes should be 
viable, provided that the adduct from the first step would be less 
reactive than the initial substrate. Thus, when the first MCR 
takes place, the intermediate adduct would bear untouched 
functional groups with altered electronic properties (ie, less 
electrophilic) in comparison with those in the starting material, as 
a consequence of the initial structural modification. In this way, 
the reaction could proceed selectively, enabling a second MCR 
with a different set of inputs. Also, in cases involving non-
symmetrical starting materials, the reactivity of the repeated 
functional groups should be kinetically distinct (Scheme 1A). 
Moreover, as the choice of multiple MCRs is rather limited to Ugi 
reactions (apart form few reported processes),13-15 the expansion 
of their scope would be highly beneficial.  
Furthermore, the use of heterocyclic inputs, privileged motifs 
in drugs, yields meaningful MCR adducts.16 Polyamino-
polyazines are attractive, yet unexplored MCR substrates. For 
instance, diaminopyrimidines are relevant in medicinal 
chemistry,17 while melamine plays a key role in materials 
science.18  
The Groebke-Blackburn-Bienaymé reaction (GBBR), which 
involves the acid-catalyzed interaction of α-aminoazines, 
aldehydes and isocyanides to yield imidazoazines (Scheme 
1B),19-21 important adducts in drug discovery,22 represents an 
ideal candidate to embed in a novel highly ordered MCR 
process. We hereby disclose our results on selective multiple 
GBBRs (Scheme 1C). 
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Scheme 1. Selective Multiple Multicomponent Reactions (A) Concept of selective multiple MCRs. (B) Groebke-Blackburn-Bienaymé reaction (GBBR). (C) Present 
work: selective multiple GBBRs. 
Results and Discussion 
Multiple GBBRs: Reactivity and Scope 
We first examined the GBBR of 4-chlorobenzaldehyde and 
cyclohexyl isocyanide (two equivalents each) with 2,4-
diaminopyrimidine 1a. Initial screening of reaction conditions (SI) 
showed that the expected multiple MCR adduct 5a (70%) was 
formed under p-toluenesulfonic acid (PTSA) catalysis in DMF 
(Scheme 2A). Using a variety of common aldehydes and 
isocyanides, the double GBBR adducts 5a-5f (36%-95%, 
Scheme 2A) were prepared. The innate selectivity of the 
aminoazine 1a was then studied using mixtures of two 
aldehydes and two isocyanides of distinct reactivity.23,24 
Although unsymmetrical adducts were detected in over-
statistical ratios, the complexity of the mixtures precluded any 
practical use (SI).  
Thus, we addressed a sequential approach by forming one 
mono-GBBR adduct first, then reacting this intermediate with a 
distinct aldehyde-isocyanide pair to yield the double non-
symmetrical compound. Equimolar amounts of aminoazine 1a, 
aldehyde 2a and isocyanide 3a were reacted with Yb(OTf)3 
catalysis in Acetonitrile under microwave irradiation, leading to 
the selective formation of mono-GBBR adduct 4a (80%, Scheme 
2A, structure confirmed by X-Ray, SI). Then, this compound 
underwent a second GBBR with aldehyde 2b and isocyanide 3a 
under PTSA catalysis in DMF affording the expected product 5g 
(36%, Scheme 2A, X-Ray in SI), enabling selective multiple 
MCRs with full control on all four diversity points of scaffold 5. In 
this way, a variety of mono- and di-GBBR adducts 4a-g (23%-
93%)25 and 5g-m (13%-57%) respectively, were formed using 
this protocol (Scheme 2A). Incidentally, on the course of a 
GBBR upon adduct 4d, a lactamization took place giving the 
pentacyclic adduct 5n (7%, Scheme 2E).  
To show the power of our approach, we prepared the 5CR 
adducts 5h (50%) and 5j (40%), displaying the same 
substituents in complementary positions, merely changing the 
order in which the MCRs were performed (Scheme 2A). The 
aldehyde/isocyanide scope of these multiple MCRs is basically 
the same found in standard GBBRs.  
Next, we explored the range of the aminoazine component. 
Diaminoquinazoline 1b (Scheme 2B) underwent a regioselective 
GBBR yielding mono-adduct 6a (65%). In a different reaction, 
substrate 1b the symmetrical bis-adduct 7a (78%). Moreover, a 
second GBBR, performed upon 6a, gave the non-symmetrical 
compound 7b (43%, Scheme 2B).  
Diamino-pyridazine 1c afforded the mono GBBR adducts 8a-
d (24%-60%). The symmetrical and non-symmetrical double 
GBBR adducts 9a (38%) and 9b (36%) were also prepared 
(Scheme 2C). Interestingly, with substrate 1c, the di-GBBR 
adducts were only formed using aromatic isocyanides, whereas 
bulkier ones (tert-butyl) failed to react, likely due to the steric 
clash of the proximal amines in the putative structure. 
Remarkably, the mono GBBR adducts 8, upon interaction with 
an isocyanide, an aldehyde and a carboxylic acid underwent a 
standard Ugi reaction to yield the new scaffold 10. Adduct 10a 
(14%, unoptimized) was directly isolated in a one-pot process 
involving a spontaneous GBBR-Ugi sequence in the presence of 
AcOH (first catalyzing the GBBR and then reacting in the Ugi 
step). 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
FULL PAPER    
 
 
 
 
 
 
Scheme 2. The scope of the multiple GBBRs A) GBBRs and double GBBRs of diaminopyrimidine 1a and the synthesized library. B) Diaminoquinazoline 1b in 
multiple GBBRs. C) GBBR, double GBBRs and GBBR-Ugi upon diaminopyridazine 1c and the synthesized library. D) Melamine (1d) triple GBBR processes. E) 
Lactam 5n.  
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Adducts 10b (77%) and 10c (61%), featuring five diversity points, 
were thus prepared from the corresponding mono adducts 
(Scheme 2C). 
Finally, we tackled melamine (1d), a key key reactant with 
widespread use. However, its reactivity is troublesome due to its 
poor solubility in most organic solvents, thus having remained 
unexplored in MCRs. Using our PTSA method, we generated 
the triple adducts 11a-e (31%-57%, Scheme 2D, 11a X-Ray 
crystallography in SI). Scaffold 11 is a novel tripodal, compact, 
N-fused tetracyclic nucleus, conveniently synthesized in a formal 
7CR, featuring the formation of nine bonds in a single step. The 
selective formation of melamine non-symmetrical adducts is not 
yet feasible and studies towards this goal are ongoing. 
Post-Condensation Transformations 
Post-transformations of MCR adducts can diversify the initial 
scaffolds, leading to complex and valuable chemotypes. In this 
way, our GBBR cores were modified through a number of 
representative reactions. The pyridine rings in adduct 5b were 
alkylated with iodomethane to give salt 12 (78%, Figure 1A). 
This selective alkylation reflects the higher reactivity of the 
DMAP-like moieties. Additionally, 2,5-diketopiperazine 13 (43%), 
a relevant scaffold in medicinal chemistry,26 was generated from 
the GBBR-Ugi adduct 10c (Figure 1B).27 
N-fused polycyclic structures, resembling N-doped 
nanographene ribbons,28 are valuable in materials science, 
although their preparation entails complex multistep sequences. 
  
 
Figure 1. Post-Transformations of Multiple GBBR Adducts. A) Pyridinium salt 12. B) Diketopiperazine 13. C and D) Ullmann-type adducts 14 and 15. E, F and G) 
Suzuki-Miyaura cross-coupling adducts 16a-c and molecular packing arrangement of compound 16c. New bonds marked in magenta, added residues in pink. 
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In this context, GBBR adducts were subjected to metal-
catalyzed cross-couplings. Intramolecular Ullmann-type 
amination upon adduct 5f yielded the heptacyclic compound 14 
(67%, Figure 1C). The same transformation upon 11b 
successfully gave the decacyclic radial derivative 15 (47%, 
Figure 1D). Tetracyclic adducts 11c-d, fitted with aryl iodide 
residues, reacted with arylboronic acids via multiple Suzuki-
Miyaura cross-couplings to access star-shaped compounds 16a-
c (31-49%, Figure 1E-G). Remarkably, compounds 16b-c have 
nanometric dimensions, the latter reaching almost 30 Å length. 
Its X-Ray diffraction shows a regular molecule with a planar core 
and some degree of conformational freedom around the 
cyclohexyl residues (Figure 1G and SI). The crystal packing 
features an interesting docking arrangement of the central π 
system with intertwining of the triaryl groups (Figure S2 in SI). 
These examples notably demonstrate the power of the 
methodology to build functionalized nanosized entities through a 
direct bottom-up approach. 
Computational Studies of Mechanism Pathways 
The regioselective formation of mono-GBBR adducts 4 
(Scheme 2A) is key for the synthetic usefulness of the approach. 
This outcome is the result of two crucial steps, the first one 
involving the imine formation since the preferential attack of the 
amino groups at positions 2 or 4 may be relevant to the 
selectivity (Scheme 3). To this end, M062X/6-31+G(d) 
calculations29,30 (SI) were performed to identify the transition 
states (TSs) formed along the corresponding pathways. The TSs 
formed via addition of the amino group in position 2 are ≈ 3 
kcal/mol more stable than the ones generated upon attack at 
position 4. The 2-amino tetrahedral adduct is favored by 4.6 
kcal/mol relative to the corresponding amino-4 species. Finally, 
loss of a water molecule leads to two almost isostable 
protonated imine conformers, which are more stable (5.7 
kcal/mol) than the 4-amino counterparts. The second step 
involves the cyclization of the adduct formed upon addition of 
the isocyanide to the imine derivative. 
This process preferentially takes place through intermediate 
I12a, leading to an adduct where the nitrilium carbon atom may 
face either the N1 or N3 in the pyrimidine ring, the former 
conformer being favored by 2.6 kcal/mol. Cyclization occurs via 
the attack of the azine nitrogens to the nitrilium C atom through 
an almost barrierless process for N1, whereas for N3 the 
transition is less favourable. Therefore, the conformational 
preference of the intermediate (I22,1) dictates the formation of the 
final product 4. Overall, the selectivity appears to arise from the 
combined effect of the preferential formation of one imine (from 
the amino group at position 2) and its subsequent isocyanide 
addition/cyclization via the azine N1. These results support the 
feasibility of selective multiple MCRs involving difunctionalized 
substrates. 
Applications in Chemical Biology and Medicinal Chemistry 
To determine the usefulness of our methodology to access 
and tune valuable scaffolds, we explored the performance of the 
synthesized compounds in a number of disciplines related to 
biomedicine. As a proof of concept, we intended to show that the 
reported approach would rend functional compounds, amenable 
to fast optimization. 
 
Scheme 3. Mechanistic Rationale for the Selective Multiple GBBRs: Reaction pathways from the interaction between 2,4-diaminopyrimidine (1a), benzaldehyde 
(2) and cyclohexyl isocyanide. The relative free energies (kcal/mol) are shown in blue.  
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Figure 2. GBBR Adducts as Fluorophores: A) Chemical tunability of the fluorescence emission of different GBBR adducts. B) Selective formation of the 5-
membered BODIPY-like fluorophore 18a and its X-Ray diffraction. C) Probe 18b. D, E, F) Comparative photophysical analysis of the adduct 18a (in green) and its 
precursor 17 (in black). 
i) Bioimaging Studies of Selected Multiple GBBR Adducts 
The need for novel functional fluorophores has prompted the 
development of new synthetic strategies to prepare probes not 
accessible through classical synthesis,31 and MCRs constitute a 
valuable platform to afford them.32,33 The versatility of the novel 
multiple GBBRs allows the fine tuning of the structural and 
spectral properties of the adducts. Particularly, we controlled 
their red-shifted fluorescence emission wavelengths by 
extending their electronic conjugation with connected aryl 
groups (12 vs 5b and 9a, Figure 2A). Our approach also 
enabled the introduction of electron-withdrawing and electron-
donating groups at specific sites to generate push-pull 
fluorophores with bright fluorescence emission in the orange-to-
red region (10a, Figure 2A). Notably, a number of GBBR 
adducts behaved as activatable fluorophores, with emission 
intensities depending on the microenvironment (Table S2, 
Figures S6-S7 in SI).  
The excellent photophysical features of the BODIPY scaffold 
in bioimaging,34,35 encouraged us to explore the generation of 
novel BODIPY fluorophores arising from α-pyridyl-GBBR 
adducts. Remarkably, model GBBR compound 17 reacted with 
BF3 to selectively render complex 18a
 (Figure 2B), which 
displays a BF2 bridge linking the imino group and the pyridine 
nitrogen, suggesting that the formation of the 5-membered ring  
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Figure 3. Brightfield and fluorescence confocal microscope images of human A549 epithelial cells upon incubation with compound 18a (2 µM, green signal) and 
the commercially available trackers LysoTracker Red (red signal) and MitoTracker Red (red signal). Scale bar: 10 µm.  
is faster than the conventional 6-membered BODIPY cycle.36 
Analogously, the BODIPY-like compound 18b was obtained 
from the double GBBR adduct 5d (Figure 2C).  
Notably, compound 18b showed pH-dependent fluorescence 
emission, with a pKa of 5.0 and brighter fluorescence in basic 
media, unlike the majority of BODIPY dyes. Next, the 
photophysical features of the probe 18a were analyzed and 
compared with those of its precursor. Besides exhibiting a 
remarkably longer emission wavelength (453 nm to 514 nm, 
Figure 2D), compound 18a featured a 40-fold higher 
fluorescence quantum yield, presumably due to the increased 
rigidification of the BODIPY core (Figure 2E). Unlike its 
precursor 17 (or 18b), the fluorescence emission of compound 
18a did not show meaningful pH dependence, asserting its value 
as a bright green fluorophore for bioimaging assays covering a 
broad range of pH values (Figure 2F, SI).  
We also confirmed the compatibility of probe 18a for live-cell 
imaging by incubating human lung A549 epithelial cells and 
acquiring images under a confocal fluorescence microscope. 
Fluorophore 18a showed excellent cell permeability and 
preferential accumulation in the mitochondria, as demonstrated 
by co-incubation with the commercially available LysoTracker 
and MitoTracker dyes (Figure 3, SI). These results indicate the 
suitability of multiple GBBRs to generate novel fluorescent 
scaffolds with excellent features for bioimaging studies.  
ii) Antiviral Activity of Multiple GBBR Adducts 
We determined the therapeutic potential of multiple GBBR 
scaffolds22 against human adenoviruses (HAdV). While 
responsible for mild diseases in healthy individuals, HAdV 
infections are associated with high mortality in 
immunosuppressed patients.37 The lack of approved specific 
antiviral drugs with efficacy and safety against HAdV further 
complicates the treatment of these patients.38 In this context, 
representative GBBR adducts (Table 1 and Figure S11 in SI) 
were tested against HAdV using different susceptibility assays. 
Remarkably, five members of this chemset displayed significant 
anti-HAdV activity in the plaque assay, when evaluated at a 
concentration of 10 µM (Table 1, SI). Among these, compounds 
5h and 5n presented a dose-dependent activity, with IC50 values 
of 1.19 and 3.42 µM, respectively, and high selectivity indexes 
(94 and 62, Table 1). The most cytotoxic molecule, 5b presented 
the lowest selectivity index. Interestingly, compound 10b (dose-
independent, inactive below 10 µM) displayed a relevant virus 
yield reduction (157-fold, Table 1). In relation with frequently 
used antivirals, cidofovir, the drug of choice for HAdV infections, 
showed a significantly lower potency (IC50 ≈24 µM). These 
results are encouraging given the observed structure-activity 
relationships. In particular, GBBR adducts 5g and 5h, sharing 
the same diaminopyrimidine scaffold, display very different 
bioactivity (Table 1, SI). Also adduct 10b is considerably more 
active than the close analogue 9a. This trend strongly suggests 
that the bioactivity profile could be further improved through 
programmed exploration around this chemistry.  
 
Table 1. Inhibitory HAdV activity of multiple GBBR adducts 
Adduct IC50 (µM) CC50 (µM) S.I
 [a]
 V.Y.R
 [b]
 
5b 2,46±0,00 22,90±2,24 9 115,42±59,76 
5h 1,19±0,08 112,50±2,94 94 11,54±5,98 
5n 3,42±1,33 215,22±8,53 63 24,88±12,87 
10a ≤ 10
 [c]
 62,80±12,53 --- 11,54±5,98 
10b ≤ 10
 [c]
 132,2±1,41 --- 157,72±0,00 
[a] Selectivity index. [b] Virus yield reduction (fold-reduction). [c] The IC50 
could not be determined. 10a and 10b do not show a dose-dependent 
effect, although they are active at 10 µM. 
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iii) Affinity of Multiple GBBR Adducts to DNA 
Since DNA displays a variety of different structural types, it is 
crucial to have selective binders to study their roles as a 
preliminary step to develop medicines.39 Especially relevant are 
G-quadruplexes, because of their wide presence in the genome, 
mainly involved in the maintenance of chromosomes and in the 
transcriptional regulation of genes.40 Topology-dependent 
ligands, selectively binding quadruplexes, will therefore have a 
significant impact on biological and medicinal chemistry.41 Flat 
N-heteroaromatic motifs with polar or cationic groups are 
frequently found in active binders, stabilizing the G-tetrads by -
stacking and electrostatic interactions, although they are often 
non-selective for a defined substructure.  
In this context, we explored a subset of our GBBR adducts 
(5b, 11b, 12 and 18b) in the interaction with model DNA 
oligonucleotides. Competitive dialysis experiments42 were 
performed with ten oligonucleotides representing prototypical 
DNA structures (Table S4 in SI): single-strands, double-strands 
and, especially, G-quadruplexes, representing different 
topologies (parallel, antiparallel and hybrid), some of which are 
sensitive to binders causing downregulation of oncogene 
expression.43 Melamine adduct 11b interacts with all DNA 
sequences, being significantly more intense with the single 
strand T20. Compound 5b showed a non-specific, weak affinity 
for several sequences (SI). However, its dimethylated salt 12 
remarkably displayed a potent and selective affinity for the 
hybrid quadruplex 24blc (Figure 4B). The cationic nature of 12 
may explain its stronger interactions in comparison with those of 
adduct 5b. The charged BODIPY-adduct 18b showed affinity 
again for 24bcl (Figure 4A). 
To study the interaction of compound 12 with quadruplexes, 
we carried out fluorescence titrations of sequences GG1 and 
24bcl (hybrid quadruplex) with double strand DS26 as the 
negative control (Figure S15 in SI). The titration curves showed 
that raising the relative oligonucleotide-drug concentration up to 
18-fold, resulted in a significant increase (≈5-fold) in the 
fluorescence of the combination 24bcl-12. A similar, yet less 
potent, behaviour (≈3-fold), was detected with GG1. However, in 
the case of interaction with DS26, no significant change was 
observed (Figure 4C). Considering that oligonucleotides are 
non-fluorescent, and that the drug concentration is constant, the 
observed increase in fluorescence arises from the formation of 
oligomer-drug complexes.  
 
 
Figure 4. DNA Binding Studies of Multiple GBBR adducts: A, B) Competitive dialysis assays of ten oligonucleotide sequences with compounds 18b and 12. C) 
Fluorescence titration of a 0.2 μM solution of the GBBR adduct 12 after addition of increasing amounts of oligonucleotides DS26, GG1 and 24bcl (from 0 to 10 
μM) in potassium phosphate buffer. 
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These results indicate that compound 12 has selective affinity to 
quadruplex DNA structures, especially 24bcl (Figure 4B, C) and 
may serve as a lead to develop new selective binders, a 
promising way to generate novel anticancer drugs. 
Conclusions 
In summary, we have developed a rationale for selective 
multiple MCRs, by performing GBBRs involving heterocyclic 
di/triamines, substantially expanding the scope for these 
processes. Their feasibility is based on sequential processes 
exploiting the higher reactivity along preferred evolutionary 
pathways, discriminating between nearly identical functional 
groups. The mechanism of these selective transformations was 
established by means of computational methods. This 
sequential mode allows the programmed incorporation of 
substituents at up to 5/6 diversity points. As a proof of concept, 
the resulting adducts, which would be impossible or extremely 
challenging to prepare by alternative synthetic pathways, display 
remarkable properties as antivirals, fluorescent probes, selective 
DNA binders and nanometric blocks. Moreover, their fast and 
controlled synthesis would enable the straightforward tuning of 
their properties. The general character of this approach and the 
applications of the ensuing scaffolds will significantly expand the 
reach of selective multiple MCRs in biology and medicine 
Experimental Section 
Full account of the experimental procedures is provided in the 
Supplementary Information. It includes experimental protocols, 
compound characterization data, copies of the spectra, X-ray description 
of some adducts, details on the computational studies, bioimaging 
experiments, antiviral studies, and DNA binding determinations.  
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Multiple & selective: A rationale for 
selective multiple Multicomponent 
Reactions was developed and 
implemented in Groebke-Blackburn-
Bienaymé transformations with a 
range of polyamino-polyazines to yield 
novel chemotypes, fitted with up to 5 
diversity points. The generated 
adducts display impressive 
performance as live cell fluorescent 
probes, selective G-quadruplex 
binders, and antiviral agents. 
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